Gilead earnings buoyed by Hepatitis-C drug By: MarketWatch April 22, 2014 at 16:47 PM EDT Sales of $1,000-a-pop Solvadi drug soar, helping earnings to triple Read More >> Related Stocks: Gilead Sciences